Interestingly, the use of C3 inhibitor abrogated the immunosuppressive response of intra-tumor neutrophils, suggesting that complement inhibition could be a promising therapeutic strategy for ovarian cancer in which suppressive neutrophils impaired anti-tumor immunity response [112]. Here, C3 is linked to neoplasm.